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Abstract.  Human polymorphonuclear leukocytes 
(PMN) released large quantities of hydrogen peroxide 
in response to tumor necrosis factor, but only when 
the cells were adherent to surfaces coated with ex- 
tracellular matrix proteins.  The PMN did not respond 
when exposed to cytokines and matrix proteins in sus- 
pension,  or when exposed to cytokines while adherent 
to surfaces coated with stearic acid.  PMN from chil- 
dren with genetic deficiency of the CDll/CD18 inte- 
grins underwent a normal respiratory burst upon ad- 
herence to uncoated polystyrene, but not in response 
to tumor necrosis factor when tested on polystyrene 
that was coated with serum,  fibronectin, vitronectin, 
fibrinogen, thrombospondin,  or laminin.  Anti-CD18 
antibodies, alone of sixteen antibodies tested,  induced 
a  similar defect in PMN from normal donors,  when 
the PMN were tested on surfaces coated with serum, 
fibrinogen, thrombospondin,  or laminin;  no defect was 
induced by the anti-CD18  monoclonal antibody IB4 in 
normal PMN tested on surfaces coated with fibronec- 
tin or vitronectin.  Thus,  for cytokines to induce a re- 
spiratory burst in PMN, the cells must be able to use 
CDll/CD18 integrins  and must interact with matrix 
proteins in the solid phase.  CDll/CD18,  which is al- 
ready known to serve as a  receptor for fibrinogen, 
may also be a receptor for thrombospondin and lami- 
nin.  Finally,  receptor(s) exist on PMN for fibronectin 
and vitronectin which are not blocked by the 
anti-CD18 antibody IB4 but which are nonetheless 
CDll/CD18 dependent. 
H 
UMAN polymorphonuclear leukocytes (PMN) ~ can 
undergo a large respiratory burst in response to sub- 
nanomolar concentrations  of tumor necrosis factor- 
ct (TNFo0,  TNF/$,  colony stimulating  factor  for granulo- 
cytes and macrophages  (CSF-GM),  or colony stimulating 
factor for granulocytes (CSF-G), but only if the PMN are ad- 
herent to surfaces coated with plasma, serum, or proteins of 
extracellular  matrix (40, 41). There are few if any other in- 
stances in which adherence of PMN capacitates  them to re- 
spond to stimuli  that are otherwise ineffective. The goal of 
the present study was to determine if capacitation  by adher- 
ence requires ligation  of specific adhesion receptors. 
Integrins  are a superfamily of heterodimeric,  transmem- 
brahe glycoproteins which act as receptors for various glyco- 
proteins of extracellular  matrix or cell surface (33). Interac- 
tion of integrins with surface-bound ligands supports adhesion 
1. Abbreviations used in this paper: CSF-G, colony stimulating factor for 
granulocytes; CSF-GM, colony stimulating factor for granulocytes/macro- 
phages; FBG, fibrinogen; FN, fibronectin; KRPG, Krebs-Ringer phosphate 
buffer with glucose; LAD, leukocyte adhesion deficiency; LAM, laminin; 
PMA, phorhol myristate acetate; PMN,  neutrophilic polymorphonuclear 
leukoeytes; r, recombinant; TNE tumor necrosis factor; TSP, thrombospon- 
din; VN, vitronectin. 
of phagocytes and their spreading,  diapedesis,  and phagocy- 
tosis.  Engagement  of phagocyte integrins  apparently does 
not trigger secretion, for example of hydrogen peroxide (23, 
66) or arachidonate  (1), although  exposure of macrophages 
to an anti-integrin  antibody for 1-3 d did increase the amount 
of hydrogen peroxide released subsequently in response to a 
secretagogue (23). 
A family of integrins apparently restricted to leukocytes is 
comprised of CDlla/CD18  (LFA-1), CDllb/CD18 (Macd, 
complement receptor type 3),  and CDllc/CD18 (p150,95) 
(34, 54). Leukocyte adhesion deficiency (LAD) is a genetic 
disease resulting  from markedly decreased cell surface ex- 
pression of all three of these heterodimers,  a consequence of 
deficiency  or abnormality in mRNA for CD18  (34).  The 
function of CDll/CD18 molecules in cell adhesion has been 
inferred from the defects displayed by PMN of children with 
LAD or by normal PMN treated with anti-CDll  or anti- 
CD18 antibodies (5,  11,  19, 26, 47, 59, 69).  PMN in LAD 
patients migrate poorly through tissues to sites of inflamma- 
tion, and, like normal PMN treated with anti-CDll or an- 
ti-CD18 antibodies,  attach and spread poorly in vitro.  The 
in vitro studies have dealt with adherence of PMN to surfaces 
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plastic,  or nylon wool; glass or plastic coated with serum; 
or cultured endothelial  cells.  Four specific  protein ligands 
for CD11/CD18  have been  identified:  C3bi  (65),  ICAM-1 
(39), coagulation factor X (4), and fibrinogen (FBG) (2, 68). 
Of these,  only  FBG  can be  considered  a  matrix  protein. 
Thus, while it is likely that CD11/CD18 molecules interact 
with matrix components,  there is little information on the 
specificity of CDll/CD18 integrins for individual proteins of 
extracellular matrix. 
Using  PMN  from  children  with  LAD,  normal  PMN 
treated  with  anti-integrin  antibodies,  and  surfaces  coated 
with purified matrix proteins,  the present work shows that 
solid-phase  FBG,  thrombospondin,  laminin,  fibronectin, 
and vitronectin capacitate PMN to secrete hydrogen peroxide 
in response to cytokines. Each of these interactions requires 
expression of CDll/CD18  molecules on the PMN. 
Materials and Methods 
PMN 
Donors of venous blood (collected with heparin) were three children with 
LAD  whose clinical histories have been described (Detmers,  P.,  S.  D. 
Wright, E. Olsen-Egbert, R. Adamowski, Z. Chad, L. B. Kabbash, and 
Z. A. Cohn, manuscript in preparation), the parents of one of them, three 
other children referred for evaluation of leukocyte function defects, and 
seven healthy adults. Blood from the LAD patients and a normal donor was 
collected in Montreal, brought to New York  by courier,  and processed 
within •5  h of collection, together with blood that was processed immedi- 
ately after collection from an additional normal donor in New York. Results 
were comparable for either source of normal donors' cells. For assays of 
H202  release, PMN were isolated on a one-step Ficoll-Hypaque gradient 
(Nentrophil Isolation Medium;  Los Alamos Diagnostics,  Los Alamos, 
NM) as described (40), with the following modification. For patients with 
marked leukocytosis, the ratio of leukocytes to surface area of the interface 
was adjusted by layering 0.25 ml blood on 4 ml of isolation medium in a 
15-ml tube, or 61.4 ml blood on 10 ml of isolation medium in a 50-ml tube. 
PMN (/>98%  PMN, 62% lymphocytes) were washed and resuspended at 
7.5  x  IOS/ml in Krebs-Ringer phosphate buffer with glucose (KRPG) (40). 
For determination of CDII/CDI8 levels, PMN were purified on a two-step 
Ficoll-Hypaque gradient as described (24) and resuspended in RPMI con- 
taining human serum albumin and aprotinin.  Levels of CDlla,  CDllb, 
CDllc, and CD18 on the surface of unstimulated PMN were measured by 
flow cytometry using mAbs TS1/22,  OKM10, Lee M5, and IB4, respec- 
tively. In addition, phorbol myristate acetate (PMA) was added to mobilize 
possible intracellular reserves of CDll/CDI8 molecules to the cell surface 
(7, 10, 53), as monitored by rosetting of erythrocytes coated with comple- 
ment component C3bi. By both assays, CDI1/CDI8 molecules were ;~96% 
deficient on cells from each of the three LAD patients, were not measured 
but presumed normal on cells from two of the healthy adults,  and were 
documented to be normal on PMN of all other donors. 
Preparation of  Surfaces 
Initial studies used tissue culture grade polystyrene plates with 6-mm-diam 
flat-bottomed wells (No. 25860; Costar Data Packaging Corp., Cambridge, 
MA); later experiments used the modified Primaria plates (No. 3872; Fal- 
con Labware, Oxnard, CA) (discussed in reference 41). The agents used, 
their sources, the amounts plated per well, and the diluent (25/zl/well) were 
as follows. FBS (HyClone Laboratories, Logan, LIT); undiluted (in some 
experiments with FBS-coated wells, the reaction solution [see below] was 
also made to contain 0.1% fresh autologous human plasma). Pure human 
plasma FBG (Sigma Chemical Co., St. Louis, MO); 100/~g in RPMI 1640 
medium (HyClone Systems, Lenexa, KS). Pure human plasma FN (New 
York Blood Center); 3.4 pg in KRPG. Laminin (LAM) (purified 995% 
from basement membrane of the Engelbreth-Holm-Swarm tumor) (Col- 
laborative Research, Inc., Waltham, MA); 0.5-10.0/~g in RPMI 1640. Hu- 
man thrombospondin (TSP);  purified from the calcium ionophore-stim- 
ulated releasate of human platelets by sequential heparin Sepharose and 
anion exchange chromatography (16, 37);  3.5-10.0 pg  in 0.15  M  NaCI. 
Vitronectin (VN); purified from human plasma by mAb and heparin affinity 
chromatography (27);  1.5-4.0/~g in KRI~. The FBG, FN, LAM, TSP, and 
VN each gave only the expected bands on polyacrylamide gel electropbore- 
sis. In other wells, 250 ~g fatty acid/50 ~tl methanol was added and the 
plates placed in a vacuum dessicator until the solvent evaporated. All plates 
were then incubated in humidified 5% CO2/95% air for 1-2 h. Wells con- 
taining protein were washed three times with 0.9% NaCI.  Each well was 
then given 100/,1 of KRPG containing 2.4-3.5 nmol scopoletin, 0.5/~g of 
horseradish peroxidas¢, and  1 mM NaN3  (reaction solution). Triggering 
agents and antibodies were added in 10/~1. Plates were incubated at 37"C 
in air for 30 min before addition of cells (1.5  x  104/20/zl per well). 
Treatment of  PMN with Antibodies 
PMN were exposed to the antibodies listed in Table I while in agitated sus- 
pension in FBS-coated tubes as follows. Polypropylene microfuge tubes 
(Brinkmann Instruments Co., Westbury,  NY) were coated with FBS by end- 
over-end rotation at 3-/°C for 1 h. The tubes were washed extensively with 
0.9 % NaC1. Antibodies were added (where indicated, addition of  antibodies 
was delayed), followed by PMN to a final concentration of 7.5  ×  105/ml 
in KRPG in a volume of  0.5-1.2 ml per tube of 1.5 ml capacity, or 0.24-0.38 
ml per tube of 0.5 ml capacity. The tubes were shaken mechanically at 150 
horizontal cycles/rain at 37°C for 90 rain. 20/~1 of cell suspension was then 
transferred to each well. Wells contained sufficient additional antibody to 
maintain the stated concentration. In some experiments with antiserum, 
PMN were washed after preincubation, and antiserum was not added to the 
wells, to avoid coating the wells with serum proteins. Bubbles in the wells 
were popped with a 26-gange needle to avoid fluorescence artefacts. PMN 
preincubated as described above could release as much H202  in response 
to PMA as PMN from the same preparations tested without preincubation. 
However, results were markedly inferior if the cell density during preincu- 
hation was fivefold lower, the volume of cell suspension per tube threefold 
lower, the agitation 1.4-fold faster, the tube made of polystyrene, the coating 
with FBS omitted, or the suspension allowed to remain stationary at any 
time before the cells were transferred to the plates. In each experiment it 
was demonstrated that antibody treatment itself  elicited no peroxide release. 
1-1202 Release 
Triggering agents included pure, recombinant (r) TNFot and frNF/~ (Ge- 
nentech, Inc., South San Francisco, CA), rCSF-GM and rCSF-G (Amgan, 
Inc., Thousand Oaks, CA, and Genetics Institute, Cambridge, MA), and 
PMA. The cytokines have been described (40, 41). Except in dose-response 
studies, all triggering agents were used at 100 ng/ml, which affords a maxi- 
mal response (40, 41). H202 release was measured at 15-rain intervals dur- 
ing a  2-h  incubation in air at  37°C by the decrease in fluorescence of 
seopoletin as measured by a plate-reading fluorimeter (Flow Laboratories, 
Inc., McLean, VA). Results were calculated as described (21). Each condi- 
tion was tested in triplicate. When most of the SEM within one experiment 
were smaller than the symbols used in the figure, SEM have not been dis- 
played. Where pooled data are reported, they represent means +  SEM from 
the indicated number of separate experiments, each datum being the mean 
of triplicates from one experiment. 
TNF Receptors 
Specific binding of 125I-rTNFt~ to PMN was measured as reported (48). In 
brief, 2  x  l0  s PMN in 0.2 ml KRPG containing 5 mM NaN3  and  10% 
FBS were incubated with 125I-rTNFa (4 x  los cpm)  on a rocking platform 
for 4 h at 4°C with or without 100-fold excess of unlabeled r'I'NF~ washed 
four times by centrifugation, and counted in a gamma spectrometer. 
Reagents 
Where not otherwise stated, reagents were from Sigma Chemical Co. Bac- 
terial lipopolysaccharide contamination of reagents was monitored by the 
chromogenic limulus amoebocyte lysate test (Whittaker M. A. Bioproducts, 
Walkersville, MD) and found not to exceed 20 pg/ml at the concentrations 
used. 
Results 
Previous studies (40, 41; Nathan, C., unpublished observa- 
tions) established that uncoated polystyrene or glass surfaces 
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Antibody  Type and class  Specificity  Reference No. 
IB4  Mouse mAb IgG,.  CDI8  63 
60.3  Mouse mAb IgG,.  CDI8  9 
TSl/22  Mouse mAb IgG,  CDI la  50 
OKMI  Mouse mAb IgG2b  CDllb  12 
904  Mouse mAb IgGj  CDI lb  20 
Leu M5  Mouse mAb IgG2b  CD1 lc  36 
BH2C6  Mouse IgM  p157 of human PMN (not CDI 1)  46 
Anti-VLA-B  Rabbit serum  FN,  LAM,  collagen receptors  30 
B6HI2  Mouse mAb IgG~  PMN FN receptor  13 
Anti-VNR  Rabbit IgG  VN receptor  51 
OKM5  Mouse mAb IgGt  CD36; platelet gp IV; 
TSP receptor  6,35,52 
8A6-D11  Mouse mAb IgGt  CD36:  see OKM5  * 
7E3  Mouse mAb IgG,  Piatelet gp Ilb/IIIa; 
receptor for FN,  FBG, VN, 
yon Willebrand factor  17 
9.3F10  Mouse mAb IgG2,  HLA class II  55 
3C10  Mouse mAb IgG2b  p55 of mononuclear phagocytes  55 
R24  Mouse mAb lgG3  Ganglioside GD3  32 
* BarnweU, J., A. Asch, M. Maya,  and M.  Aikawa, manuscript submitted  for publication. 
triggered a respiratory burst from PMN without additional 
stimulation. Polystyrene or glass coated with plasma,  FBS, 
FBG, FN, TSP, VN, or LAM no longer triggered a respira- 
tory burst, but allowed PMN to mount a respiratory burst in 
response to cytokines. In agitated suspension, PMN did not 
respond to cytokines, even when matrix proteins were added 
in solution.  These  observations  indicated that responsive- 
ness to cytokines required adherence of PMN to a surface 
coated with certain proteins, but did not prove that these pro- 
teins had a role more specific than preventing polystyrene or 
glass  from triggering the respiratory burst. 
Cytokine-stimulated HzD2 Secretion Specifically 
Requires Adherence to Surfaces Coated with 
Certain Proteins 
To test the specificity of adherence to matrix proteins for en- 
abling a  response,  we compared frNF~induced  H202 se- 
cretion from PMN on plastic surfaces coated with FBS or 
FN  to their response  on surfaces  coated with lipids.  The 
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Figure 1. A polystyrene surface coated with FN but not stearic acid 
capacitatexi PMN  to  release  H202 in  response  to  rTNFot (100 
ng/ml). The response to PMA (100 ng/ml) was not restricted by ei- 
ther surface. 
most  suitable lipid of those screened  was  stearic  acid,  by 
three criteria: (a) PMN adhered as well to plastic coated with 
stearic acid as to plastic coated with matrix proteins (22), in 
that the PMN resisted dislodgment through three cycles of 
flicking  the plates  dry and flooding them with saline (not 
shown);  (b)  stearic  acid-coated  surface  neither  triggered 
much H202 release by itself, nor (c) interfered  with the abil- 
Table II. Hydrogen Peroxide Release from 
CD  I 1/CD18-deficient  and CD11/  CD  I 8-replete P MN  : 
Triggering by Contact with Polystyrene or by Phorbol Ester 
Uncoated surface  Coated surfaces 
Donor*  (no other stimulus)t  with PMA§ 
1"1202, nmol/l.5  x  10  ¢ PMNH 
LAD-I  0.80  +  0.18 (4)  1.08 +  0.07 (17) 
LAD-2  1.38  +  0.10 (3)  1.44  +  0.08 (12) 
LAD-3  ND  1.44  +  0.06 (4) 
Mother  ND  1.03 (1) 
Father  ND  1.14 (1) 
Ped-I  ND  0.99 (1) 
Ped-2  ND  1.42 (1) 
Ped-3  ND  1.20 (1) 
Normals  1.35  -1- 0.13 (8)  1.78  +  0.06 (24) 
* LAD-l,  2-yr-old boy with leukocyte adhesion deficiency.  LAD-2, 2-yr-old 
boy with LAD. LAD-3, 4-yr-old girl with LAD. Mother and Father, mother 
and father  of LAD-I. Ped-l,  3-d-old premature  girl with unexplained neu- 
trophilic leukocytosis and negative microbiologic cultures. Ped-2, 5-yr-old girl 
with unexplained  recurrent  abscesses. Ped-3, 6-yr-old boy with unexplained 
recurrent  abscesses. Normals, seven healthy adult men. CDI I/CDIg expres- 
sion was documented to be deficient on PMN from LAD-I-3 and normal for 
all other donors, except two of the normals, on whose PMN CDI I/CD 18 were 
not tested. 
* Respiratory  burst  triggered  by contact of PMN  with  tissue  culture  grade 
polystyrene (conventional or Primaria types). 
§ Respiratory  burst triggered  by phorbol  myristate  acetate  (100  ng/ml)  in 
PMN adherent to polystyrene surfaces coaled with FBS, human plasma, FN, 
FBG, TSP, VN, or LAM; such coated surfaces induced little or no respiratory 
burst  by themselves. 
[I Mean :t: SEM for number of experiments in parentheses, each in triplicate, 
at the termination  of the response (90-120 min). 
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Figure 2.  Comparison  of H202  release  by  PMN  from  normal 
donors or LAD patients  in response to contact with an uncoated 
polystyrene surface or in response to rTNF(~ or PMA (each  100 
ng/ml)  on surfaces  coated with individual  matrix proteins. 
ity of PMA to do so. Yet,  as shown in Fig.  1, adherence to 
a stearic acid-coated surface did not capacitate PMN to se- 
crete  H202  in response  to rTNFa.  Results  were  similar  in 
six such experiments.  Thus, adherence as such was not suf- 
ficient for a response to rTNFot, but rather, adherence to sur- 
faces  coated  with particular  substances,  such as FN.  This 
raised  the possibility  that  adhesion  receptors  might  be  in- 
volved. 
Deficient Cytokine Response by PMN  from Patients 
with LAD 
PMN from each of three patients with LAD released large 
amounts of H202 over 90-120 min in response to PMA (Ta- 
ble II). These amounts averaged 74% as much as from PMN 
of the adults used  as controls  in most of the same experi- 
ments,  and equalled  or exceeded  the amounts  released  by 
Table IlL Hydrogen Peroxide Release from CDll/CD18-deficient and CDl l/CD18-replete  PMN: Triggering by rTNFt~* 
FBS  FN  FBG  TSP  VN  LAM 
Donor  Percent of PMA-triggered response$ 
LAD-I  12  4-  2  (5)  -6  4-  8  (3)  4  4-  2  (3)  8  4-  3  (4)  7  (2)  8  (1) 
LAD-2  15  4- 9 (3)  12 (2)  15 (2)  8 (2)  13 (2)  19 (1) 
LAD-3  8  (l)  15 (1)  0  (2)  0  (1)  ND  ND 
Mother  138 (1)  ND  ND  -  -  - 
Father  153  (l)  ND  ND  -  -  - 
Ped-I  128 (1)  ND  ND  -  -  - 
Ped-2  70 (1)  ND  ND  -  -  - 
Ped-3  72 (1)  ND  ND  -  -  - 
Normais  75  4-  5  (9)  95  4-  7  (3)  78  4-  7  (3)  76  +  10 (4)  92  (2)  103  (1) 
* Tissue culture polystyrene was coated with FBS,  FN,  FBG,  TSP,  VN,  or LAM before adding PMN  from the donors described in Table II. 
$ Calculated as:  100 (nmol H2Oz released in response to  100 ng/ml rTNFa minus that released without a triggering agent)/(nmol released in response to PMA 
minus that released without a triggering agent) at the same time point. Time points selected for comparison were the latest at which the H202 released without 
a triggering agent remained g'~ 10% of the response triggered by PMA, and ranged from 45 to 120 rain. Presentation of results from late time points minimizes 
the apparent deficiency in TNF-induced responses by LAD cells relative to normal cells, because responses by normal ceils tended to end earlier than responses 
by LAD cells. Results are means 5:  SEM  for the number of experiments in parentheses, each in triplicate. 
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Figure 3. Inability of high concentrations of rTNF~ to overcome the 
unresponsiveness  of PMN from LAD patients.  The surface was 
coated with FBS. 
PMN from three other children and from the healthy parents 
of one of the subjects. The normality or near normality of 
the PMA-induced respiratory burst of adherent LAD PMN 
was  consistent  with  previous comparisons of normal  and 
LAD PMN in suspension, under conditions where smaller 
amounts of respiratory burst products were measured during 
much shorter periods,  usually  <5  min  (5,  11,  19,  42).  A 
finding of special importance for the present analysis was 
that uncoated polystyrene triggered H202  release from the 
PMN of LAD patients as well as or nearly as well as from 
normal PMN (Table II and Fig. 2). Thus, in a setting where 
matrix proteins were not involved, PMN from children with 
LAD had no defect in mounting a large respiratory burst as 
a consequence of adherence. 
In contrast, LAD cells were grossly deficient in their abil- 
ity to respond to rTNFot, when assayed in plates coated with 
FBG, FN, TSP, VN, LAM, or FBS. Considering each com- 
bination of day, donor,  and surface as a  separate test,  the 
deficient rTNFo~ response of LAD cells was demonstrated in 
each of 35 trials (Table III). Fig. 2 shows such responses on 
each surface on which the responses of normal PMN have 
not been illustrated previously (40, 41). The interpatient vari- 
ability evident in Fig. 2 did not correspond to differences in 
surface expression of CD11/CD18 (see Materials and Meth- 
ods), and remains unexplained. 
The deficient response of PMN from LAD patients was not 
a consequence of quantitative insensitivity to rTNFot, since 
the defect was manifest over a  1,000-fold range of rTNFc~ 
concentrations on the plateau of the dose-response curve for 
normal PMN (Fig. 3). In five experiments with normal PMN, 
multipoint binding curves indicated the presence of 1,400 5: 
500 specific binding sites for TNF per cell with K~ of 3.9 
(5:1.8)  X  10  -9 M -l (mean 5: SEM), comparable to previous 
reports (e.g., reference 48). In two experiments involving 10 
measurements with cells from two LAD patients at three 
concentrations  of TNF,  specific binding  was  1.6-  (+0.14) 
fold as much as binding to normal PMN.  Thus,  there was 
no evidence for a deficiency of TNF receptors on LAD PMN. 
Finally, LAD PMN were also deficient in their secretion of 
H202 in response to rCSF-G and rCSF-GM (not shown). 
The deficient response of PMN from LAD patients could 
not be attributed to the patients' age, nor to effects of marked 
leukocytosis or recurrent  infection,  because no deficiency 
was evident using CDll/CD18-replete PMN from pediatric 
patients ranging in age from 3 days to 6 years. One of these 
children had marked leukocytosis and two had recurrent ab- 
scesses (Table Ill). 
Effect of  Anti-CD18 or Anti-CDll mAbs on the 
Response of Normal PMN 
The results  with  LAD patients  raised the possibility that 
CDlla, CDllb, CDllc, and/or CD18 might serve as adhesion 
receptors for each of five matrix proteins. To test this hypoth- 
esis further and to try to determine which of the CDll/CD18 
molecules was critical,  we used mAbs specific to each. 
In a previous study (40),  15 rain treatment at 4°C with 2 
#g/ml of the anti-CD18 mAb IB4 had no impact on the re- 
sponse of PMN on FBS-coated plates. We therefore exposed 
PMN to higher concentrations of mAb for longer times at a 
higher temperature. As shown in Fig. 4 a, PMN in suspen- 
sion at 37°C required >168 rain pre-exposure to 30/~g/ml IB4 
to block completely their subsequent response to fl'NFc~. Ex- 
posure for the same time at 4°C did not suffice, nor was pre- 
exposure fully effective unless followed by continued expo- 
sure to IB4 during the assay. With a 90-rain pre-exposure at 
37°C,/>90% suppression required >t10/~g/rnl IIM (Fig. 4 b). 
Using conditions optimal for inhibition by IB4 (30 #g/ml 
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Figure 4.  Ability of anti-CD18  IB4 to inhibit H202 release from 
normal PMN in response to fl'NFa on FBS-coated surfaces.  (A) 
Dependence  on duration  of earlier  exposure of PMN  to 0  or 30 
#g/ml mAb in agitated suspension at 37°C. PMN were preincubated 
for 90 rain with or without mAb before the start of the assay (time 
0). The response of adherent cells was then followed over 120 rain, 
as indicated on the abscissa. For the topmost curve, no mAb was 
added at any time. For the other curves, 30 #g/ml mAb was present 
in the assay stage. The numbers to the fight of each curve specify 
that mAb was not also present during the preincubation (0 rain) or 
was added at 22.5, 45.0, or 67.5 min before time 0. In the absence 
of TNF (100 ng/ml), no H202 was released by PMN from any of 
these groups;  results from one rTNF~free control are displayed. 
Data are means  +  SEM for triplicates. (B) Dependence of inhibi- 
tion on the concentration of 1B4. PMN were exposed to the indi- 
cated concentration of mAb in agitated suspension at 37°C for 90 
rain before the assay, as well as throughout the measurement of the 
response to rTNFc~ (100 ng/ml).  Data are means +  SEM for the 
number of experiments  shown in parentheses,  each in triplicate. 
H202 release was measured at time points selected by the criterion 
given in the legend of Table III (mean  +  SEM,  105  +  17 min), 
and averaged 1.68 +  0.19 nmol/1.5 x  l04 PMN in the absence of 
IB4. The concentration of IB4 giving 50% inhibition averaged 4.9 
+  1.0 #g/ml. 
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PMN to release H2Oz in response to rTNF~x  (100 ng/ml) during in- 
cubation on surfaces coated with the indicated proteins. PMN were 
exposed to 30 #g/ml of each mAb at 37°C for 90 rain in adwance 
of  and during the assay. Results are means + SEM from the number 
of experiments in parentheses, each in triplicate. Time points were 
selected for comparison as in Table IlI. Percent inhibition was cal- 
culated in comparison to the no-antibody control after subtracting 
H202 released without a triggering agent. 
for 90 min at 37°C before and during the assay), up to five 
other anti-CDll/CD18 mAbs were tested on each of the six 
protein-coated surfaces. As shown in Fig. 5, IB4 inhibited the 
response completely on surfaces  coated with  FBS,  FBG, 
LAM, and TSP, but not at all on FN, VN, or uncoated plas- 
tic. The latter results ruled out nonspecific effects of IB4 on 
the cells or the assay.  On FBS-coated plates,  an indepen- 
dently derived anti-CD18 mAb (60.3) was effective. How- 
ever, anti-CDlla, CDllb, or CDllc mAbs were noninhibi- 
tory on any surface tested. The anti-CDllb panel included 
mAbs  reacting with either of the known binding  sites on 
CDllb (3,  20,  62, 65). 
Lack of  Effect of Other Anti-lntegrin 
and Control Antibodies 
The foregoing results suggested that while CD18 might be 
critical to PMN interaction with surfaces coated with FBS, 
FBG, LAM, and TSP, a different integrin might be more im- 
portant in  the interaction with FN  and  VN.  However, as 
shown  in  Fig.  6,  there was  no  inhibition by anti-VLA-~ 
(which binds to FN and laminin receptors on other cell types 
[29]), 7E3 (which binds gp IIb/HIa [17], a receptor on plate- 
lets for FN,  VN,  FBG,  and von Willebrand  factor [45]), 
B6H12 (which binds to a FN receptor on PMN [13]), an anti- 
body that binds VN receptors on a variety of cells (51), or 
two mAbs (OKM5, 8A6-D11) against CD36, an 88-kD glyco- 
protein that serves as a TSP receptor on several cell types but 
which has not been detected on PMN (6, 35, 52). A variety 
of other mAbs that do or do not bind PMN served as further 
controls,  emphasizing  the  specificity of effects seen with 
IB4.  The tetrapeptide RGDS,  a  known inhibitor of many 
integrins (33), interfered nonspecifically with the peroxide 
assay at concentrations ~>70 #g/ml and thus was not informa- 
tive in this system (not shown). 
Discussion 
Substrate-bound matrix proteins and CDll/CD18  integrins 
are required for PMN to initiate a  respiratory burst in re- 
sponse to soluble cytoldnes. The ability to secrete H202 in 
response to cytokines is associated with cell spreading and 
blocked by dihydrocytochalasin B (40, 41), but not by colchi- 
cine or nocodazole (Nathan, C., unpublished observations). 
Thus, microfilaments may be involved in transmission of a 
capacitating signal from CDI1/CD18. This would be consis- 
tent with the association of some integrins with the actin- 
based cytoskeleton (33). 
We do not know how adherence capacitates secretion. With 
T  lymphocytes, antibodies that cross-link CDlla or CD18 
enhance synergistically the increase in  intracellular Ca  ++, 
release of intefleukin-2, and proliferation induced by anti- 
bodies that cross-link the antigen receptor (15, 57).  With 
PMN,  binding of CDll/CD18  to extracellular matrix pro- 
teins (but not binding by soluble mAbs) may likewise capaci- 
tate responses triggered by cytokine receptors. PMN adhe- 
sion receptors and cytokine receptors may even capacitate 
each other's functions reciprocally, generating positive feed- 
back during the lag period that precedes secretion of H202. 
Previous observations are compatible with the occurrence of 
reciprocal interactions between integrins and secretagogue 
receptors. For example, binding of FBG to the polyspecific 
platelet integrin gpIIb/IIIa is essential for intracellular alka- 
linization induced by the binding of epinephrine to the c~2 
adrenergic receptor (8),  while activation of platelets with 
thrombin promotes association of gpIlb/IIIa with the actin- 
based cytoskeleton (44). 
CD18 and/or CDll may function as receptor(s) for FBG, 
TSE and LAM, in that surfaces coated with purified FBG, 
TSP,  or LAM enabled PMN to respond to rrI'NFot; PMN 
deficient in CDll/CD18 failed to exhibit this response; and 
the response of normal PMN on surfaces coated with FBG, 
TSE or LAM  was blocked specifically by the anti-CD18 
mAb, IB4.  All three of these matrix proteins may bind to 
CDll/CD18  at  site(s)  bound by IIM or obstructed by the 
binding of IB4. Alternatively, CDll/CDI8 may be required 
for the function of receptors for these proteins. CDll/CD18 
molecules have previously been shown to bind FBG (2, 68). 
In contrast, although two distinct TSP receptors have been 
described on cells other than PMN (6, 38), an interaction of 
PMN  with TSP,  and the possibility that CDll/CD18  may 
serve as a TSP receptor, have not previously been noted. In 
future studies, the ability of CDll/CDI8 to bind TSP should 
Figure fi Lack of inhibition of the cytokine response by antibodies 
against integrins other than CDII/CDI8,  mAbs against other sur- 
face antigens of PMN, or isotype controls of irrelevant antigenic 
specificity. Anti-VLA-B  antiserum was used at 1:300. Other details 
are as in Fig. 5. 
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receptors  have been characterized biochemically on cells 
other than PMN,  some of the receptors having structural 
features of integrins (25,  49).  To our knowledge, no pre- 
vious reports  have raised the possibility that CDll/CD18 
may serve as a laminin receptor or regulate function of lami- 
nin receptors. 
PMN bind FN (13). However, an interaction of PMN with 
VN has apparently not been described. The present work in- 
dicates that PMN can interact with FN and VN via recep- 
tor(s) that are probably distinct from the receptors for FBG, 
TSP, and LAM, and from the IB4 epitope of CD18. This in- 
terpretation hinges on results that are seemingly  paradoxical. 
On the one hand, PMN could not respond to rTNF~ on sur- 
faces coated with FN or VN if the PMN were genetically 
deficient in CD11/CDI8.  On the other hand, treatment of  nor- 
mal PMN with mAb IB4 did not interfere with the ability of 
FN or VN to support a cytokine response. Of several possi- 
ble  explanations,  we will discuss two for which there  is 
precedent. 
First, there may be FN and VN receptor(s) that are struc- 
turally distinct from CD11/CD18, but whose signals must be 
transmitted via a CDll- or CD18-dependent pathway. It is 
known that information can be exchanged between integrin 
molecules: adherence of macrophages to a FN-coated sur- 
face capacitates CDllb/CD18 molecules on the nonadherent 
surface of the cell to mediate the ingestion of C3bi-coated 
erythrocytes (63). Alternatively, CD18 may be part of  the FN 
and VN receptor(s) of PMN, but FN and VN may bind to 
site(s) distinct from those recognized by or obstructed by 
mAb 1B4. A noncross-reactive pattern of inhibition by differ- 
ent mAbs supports the inference that CDllb has two to three 
different binding sites for the ligands C3bi, FBG (2), and 
phosphorylated microbial carbohydrates (62). 
Two observations suggest that CDll/CD18 molecules can 
capacitate PMN to secrete H202 in response to rTNFot by 
serving as adhesion receptors in their own right, rather than 
solely by mediating or regulating the function of other adhe- 
sion receptors. First, PMN required CDll/CD18 to respond 
on surfaces coated with FBG; CDll/CD18 molecules seem 
to comprise all demonstrable PMN binding sites for FBG (2, 
68).  Second, surfaces coated with complement component 
C3bi also capacitated PMN to respond to rTNFo~ (Nathan, 
C., and S.  Wright, unpublished observations); CDll/CD18 
molecules comprise all detectable binding sites on PMN for 
C3bi (62,  64). 
The present study did not find evidence for the involve- 
ment of integrins other than CDll/CD18 in the FN and VN 
receptor activity of PMN. Three families of integrins with 
distinct/3 chains are presently recognized:/31  or VLA, which 
includes at least two FN receptors, termed VLA-5 (ECMR 
VI) and ECMR I (28, 60);/32, consisting of the CDll/CD18 
molecules; and/33, which includes a  VN receptor and gp 
IIb/IIIa, which binds both FN and VN. The/31 family is un- 
likely to participate in the response of PMN to matrix com- 
ponents, since these molecules have been considered absent 
from PMN (28,  60). In a recent study, flow cytometry de- 
tected weak binding of an anti-VLA-fl mAb to PMN,  but 
without any difference between  PMN  from normals  and 
PMN from the LAD patients studied here (Wright, S.  D., 
P. A. Detmers, R. Adamowski, Z. Chad, L. G. Kabbash, and 
M. J. Pabst, manuscript in preparation). In the present work, 
a polyclonal antibody to the/31  chain did not inhibit the re- 
sponse of PMN on surfaces coated with FN or VN.  Simi- 
larly, with regard to r3 integrins, PMN are not thought to 
express gp Ilb/HIa, and neither a polyclonal anti-VN recep- 
tor antibody nor a mAb to gp IIb/IHa was inhibitory. A FN- 
binding protein has been purified from PMN, which reacts 
with a polyclonal anti-/33 antibody (13); a mAb against this 
protein had no effect on the response of PMN on FN. Of 
course, some of these reagents, particularly the mAbs, could 
have bound to a  relevant receptor and failed to inhibit its 
function. Thus, these studies do not rule out the participation 
of known integrins. Likewise, the possibility cannot be ex- 
cluded that the underlying defects in LAD PMN may affect 
not  just CD18 mRNA (34) but also other molecules involved 
in adhesion. 
Inhibition of the cytokine response  required prolonged 
preexposure to anti-CD18 mAb at 37°C and the continued 
presence of high concentrations of antibody throughout the 
assay. This might reflect that PMN contain a large intracellu- 
lar store of CDll/CD18 and can mobilize it to the cell surface 
(7,  10, 53).  Engagement of a small fraction of CDll/CD18 
molecules may be sufficient for a  maximal response, and 
CD11/CD18 molecules exteriorized at the site of  contact with 
the substrate may be partly protected from antibodies (61, 
67).  Prolonged preincubation at 37°C may permit endocy- 
tosed mAb to complex with intracellular CD18 before CDll/ 
CD18 molecules are mobilized to the protected sites where 
PMN make contact with the matrix protein-coated surface. 
It now appears that a secretory response of PMN can be 
controlled by ligation of three classes of receptors at the same 
time on the same cell. The ability of PMN to secrete large 
amounts of H202 in response to TNFa//3, CSF-G, and CSF- 
GM is presumably controlled by the known receptors for 
these cytokines (43, 48, 58). This response is suppressed by 
adenosine at levels found in plasma (22), an effect most likely 
mediated through the A2 receptor (18). The present results 
indicate that a third type of receptor, CD11/CD18, is required 
to capacitate this secretory response. The respiratory burst, 
which serves to kill microbes, can also cause or promote 
damage to host tissue (31). For PMN in circulation, lack of 
a  positive signal from adhesion receptors may lessen the 
likelihood of secretion in response to cytokines that have 
spilled into the blood from inflammatory sites. The secretory 
response to cytokines may normally be confined instead to 
PMN that have aggregated, adhered, or emigrated in a man- 
ner dependent in large part on CD11/CD18. Consistent with 
this speculation, experimental animals have been protected 
from inflammatory tissue damage by adminstration of anti- 
CD18 mAb (56). 
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